COPENHAGEN (Reuters) -Shares in Novo Nordisk rose in early trade on Monday, after the Wegovy-maker on Saturday dropped its ...
Novo Nordisk is raising the stakes in its push to outbid rival Pfizer for the development-stage drugmaker Metsera.
Metsera, Inc. (NASDAQ: MTSR) today announced that it has entered into an amended merger agreement with Pfizer, pursuant to which Pfizer will acquire Metsera for up to $86.25 per share, consisting of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results